person · Reporting owner
Gros David-Alexandre C
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | SVP, Chief Business Officer | December 20, 2016 | December 22, 2016 |
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Director · Chief Executive Officer | July 31, 2026 | August 04, 2026 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | President & COO | February 06, 2017 | February 09, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date December 20, 2016 · Filed December 22, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.22 · Expires 2026-12-20 | Direct | 25,000 |
Reported balance
After 2016-12-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-12-20 · Grant · Acquired 25,000 · Balance 25,000 F1: Represents the time-vested portion of the reporting person's 2016 Annual Stock Option award. The reporting person also received an option to purchase 25,000 shares of ALNY common stock that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the time-vested portion of the reporting person's 2016 Annual Stock Option award. The reporting person also received an option to purchase 25,000 shares of ALNY common stock that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests.
F2: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
Eledon Pharmaceuticals, Inc.
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 168,663 |
Ending reported balance
After 2026-07-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-31 · Grant · Acquired 354,454 · Balance 363,454 F1: Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023. Row 2 · 2026-07-31 · Tax withholding · Disposed 194,791 · Balance 168,663 F2: Represents shares withheld to pay tax withholding obligations due on the date of settlement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023.
F2: Represents shares withheld to pay tax withholding obligations due on the date of settlement.
NEUROCRINE BIOSCIENCES INC
Report date February 06, 2017 · Filed February 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock OptionSEC Table II · derivative / convertible security | Direct | 25,000 |
Reported balance
After 2017-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-06 · Grant · Acquired 25,000 · Balance 25,000 F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F2: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
F2: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 21:22 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | Tax withholdingCommon Stock | 194,791 | $3.38 | $658,393.58 |
DisclosureSEC source: 0001193125-26-333136 · ownership.xml · nonDerivative · entry 2 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,663 F2 · kind: Represents shares withheld to pay tax withholding obligations due on the date of settlement. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 21:22 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantCommon Stock | 354,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-333136 · ownership.xml · nonDerivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,454 F1 · kind: Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantRestricted Stock Units · Derivative | 66,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-004923 · ownership.xml · derivative · entry 2 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. F3 · derivative.exercise_date: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. F3 · derivative.expiration_date: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0000950170-25-004923 · ownership.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2035-01-10 F1 · derivative.exercise_date: This option represents a right to purchase up to 600,000 shares of common stock, which option vests with respect to 150,000 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 22:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 1,015,743 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000950170-24-130272 · ownership.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,015,743 Underlying: Common Stock · 1,015,743 shares Expires 2033-05-01 F1 · derivative.exercise_date: This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 1,015,743 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 380,904 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 634,839 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 517,454 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000950170-24-073772 · ownership.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,454 Underlying: Common Stock · 517,454 shares Expires 2033-05-01 F1 · derivative.exercise_date: This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 517,454 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 129,363 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 388,091 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027. Read SEC document |
| May 01, 2023 Filed May 2, 2023 22:49 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantCommon Stock (right to buy) · Derivative | 383,299 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-23-026732 · doc4.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,299 Underlying: Common Stock · 383,299 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 383,299 shares of Common Stock, which option vests with respect to 95,825 shares on May 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending May 1, 2027. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:56 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 153,600 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001209191-23-006324 · doc4.xml · derivative · entry 2 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,600 Underlying: Common Stock · 153,600 shares Expires 2032-02-01 F2 · derivative.exercise_date: This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on February 1, 2022. The option satisfied the performance criteria with respect to 153,600 shares of underlying Common Stock and these credited shares will satisfy the time-based vesting criteria with respect to 38,400 shares of Common Stock on February 1, 2023, and then with respect to 1/48th of the credited shares monthly over the three-year period ending February 1, 2026. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:56 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-23-006324 · doc4.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 300,000 shares of Common Stock, which options vests with respect to 75,000 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending February 1, 2027. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:38 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 108,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001209191-22-006492 · doc4.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,000 Underlying: Common Stock · 108,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 108,000 shares of Common Stock, which option vests with respect to 27,000 shares on February 1, 2023, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2026. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:05 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | PurchaseCommon Stock | 2,000 | $4.48 | $8,960.00 |
DisclosureSEC source: 0000899243-21-049171 · doc4.xml · nonDerivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · kind: These shares were purchased in an open market transaction in accordance with the Issuer's trading policies. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 20:05 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | PurchaseCommon Stock | 4,000 | $6.21 | $24,840.00 |
DisclosureSEC source: 0001209191-21-052519 · doc4.xml · nonDerivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 F1 · kind: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple open market transactions in accordance with the Issuer's trading policies at prices ranging from $6.20 to $6.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:25 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | PurchaseCommon Stock | 3,000 | $8.01 | $24,030.00 |
DisclosureSEC source: 0000899243-21-022998 · doc4.xml · nonDerivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: This Form 4 reports an open market purchase by the Reporting Person of shares of common stock in accordance with the Issuer's trading policies. Read SEC document |
| September 11, 2020 Filed Sep 16, 2020 00:12 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 18,278.14 | $0.00 Strike: $500.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025169 · doc4.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,278.14 Underlying: Series X1 Convertible Preferred Stock · 18,278.14 shares Expires 2020-09-11 F1 · derivative.exercise_date: This option represents a right to purchase a total of 18,278.14 shares of the Issuer's Series X1 Convertible Preferred Stock, one quarter of which will become fully vested and exercisable on September 11, 2021, with the remaining 13,708.605 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. F2 · derivative.underlying: Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Option · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008914 · doc4.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F2 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 00:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 350,000 | $0.00 Strike: $42.55 | $0.00 |
DisclosureSEC source: 0001209191-17-007325 · doc4.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2027-02-01 F1 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on February 2, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001325812-16-000110 · edgardoc.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-20 F1 · shares: Represents the time-vested portion of the reporting person's 2016 Annual Stock Option award. The reporting person also received an option to purchase 25,000 shares of ALNY common stock that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.